FDA Approves Valneva's Chikungunya Virus Vaccine
By Stephen Nakrosis
The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria.
Valneva Austria's parent company is France's Valneva SE.
The FDA said Thursday chikungunya is a mosquito-borne disease, which causes symptoms including headache, fever, joint pain and rash. The virus is an emerging global health threat, with at least 5 million cases of infection reported over the past 15 years, according to the FDA.
Ixchiq was approved for those 18 years of age and older who are at increased risk of exposure to chikungunya virus, the FDA said.
Trade in Valneva's America depositary receipts was halted after hours Thursday because of pending news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 09, 2023 18:20 ET (23:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025